期刊文献+

冠心病及2型糖尿病合并冠心病与对氧磷酯酶192Gln/Arg基因多态性的相关性研究 被引量:1

Relation between paraoxonase 192Gln/Arg gene polymorphism and coronary heart disease in and not in type 2 diabetes mellitus
下载PDF
导出
摘要 为探讨冠心病 (CHD)及 2型糖尿病 (DM )合并CHD与对氧磷酯酶 (PON1) 192Gln/Arg基因多态性的关系 ,采用多聚酶链反应 限制性片段长度多态性 (PCR RFLP)法检测了 10 4例查体健康者 (对照组 )和 76例CHD、96例 2型DM合并CHD患者的PON1 192位点的多态基因型 ;同时测量其体重指数 (BMI) ,检测总胆固醇(TC)、甘油三酯 (TG)、高密度脂蛋白胆固醇 (HDL C)、低密度脂蛋白胆固醇 (LDL C)、载脂蛋白AⅠ (ApoAⅠ )、载脂蛋白B(ApoB)。结果显示 ,PON1 192位点QQ、QR、RR基因型及Q、R等位基因频率在 2型DM合并CHD组与对照组比较均有显著性差异 (P <0 0 5、<0 0 1) ;但CHD组与对照组比较无显著性差异 (P >0 0 5 )。中国人与白种人PON1 192位点基因型及等位基因频率比较有显著性差异 (P <0 0 1)。含R等位基因的基因型QR、RR是 2型DM合并CHD的独立危险因素。提示PON1 192Gln/Arg基因多态性与 2型DM合并CHD有相关性 。 In order to investigate the relation between paraoxonase (PON1) 192Gln/Arg gene polymorphism and coronary heart disease (CHD) in and not in type 2 diabetes mellitus(DM),polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method was used to measure the PON1-192Gln/Arg genotype in 104 healthy subjects,76 patients with CHD and 96 type 2 DM patients with CHD.Meanwhile,body mass index (BMI),and serum lipid levels of all subjects were determined.Results showed that the frequency of the PON1-192Gln/Arg genotype and the allele had significant difference between type 2 DM patients with CHD and healthy subjects(P<0.05,0.01),but that had no difference between patients with CHD and healthy subjects (P>0.05).The frequency of the PON1-192Gln/Arg genotype and the allele had significant difference between Chinese and the White(P<0.01).The genotypes carried R allele were independent risk factors of type 2 DM with CHD.These suggest that PON1-192Gln/Arg gene polymorphism is associated with CHD in type 2 DM.
出处 《山东医药》 CAS 北大核心 2003年第13期1-3,共3页 Shandong Medical Journal
基金 青岛市科技发展计划项目 (No .1 999第二批 7号 )青岛市科技局 :鉴定 [2 0 0 2 ]第 1 58号
关键词 冠心病 2型糖尿病 对氧磷酯酶 基因多态性 PCR—RFLP Coronary heart disease Type 2 diabetes mellitus Paraoxonase Gene polymorphism
  • 相关文献

参考文献7

  • 1Brophy VH, Hastings MD, Clendenning JB. Polymorphlsms in the human paraoxonase (PON1) promoter. Pharmacogenetics, 2001,11(1): 77-84.
  • 2Ruiz J. Diabetes mellitus and the late complications: influence of the genetic factors. Diabetes Metab, 1997,23(2) : 57-63.
  • 3Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism(GIn192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes meIIitus. J Clin Endocrlnol Metab,1997,82(7) :2257-2260.
  • 4Ayub A, Mackness MI, Arrol S. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol, 1999, 19(2) :330-335.
  • 5Primo-Parmo SL, Sorenson RC, Teiber J, et al. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 1996,33 (3) : 498- 507.
  • 6Inoue M, Suehiro T, Nakamura T, et al. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism,2000,49(ll) :1400-1405.
  • 7Araki S, Makita Y, Cananl L, et al. Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in type 1 diabetes meUitus. Diabetoiogia, 2000, 43(12):1540-1543.

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部